Chemomab Therapeutics Ltd.
CMMB
Price:
$1.65
Market Cap:
$10.16M
Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24. This potential therapy is currently under investigation for its efficacy in managing primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Established in 2011, the company, formerly known as Anchiano Therapeutics Ltd., adopted its current name, Chemomab Therapeutics Ltd., in March 2021 and is headquartered in Tel Aviv, Israel.
Industry
Biotechnology
IPO Date
2019-02-12
Stock Exchange
NASDAQ
Ticker
CMMB
PE Ratio
[-1.47]
ROE
[-67.85%]
Current Ratio
[10.31]
Dividend Yield
[0%]
Enterprise Value
[4.25M]
Dividend History
The Current Ratio as of June 2026 (TTM) for Chemomab Therapeutics Ltd. (CMMB) is 10.31
According to Chemomab Therapeutics Ltd.’s latest financial reports and current stock price. The company's current Current Ratio is 10.31. This represents a change of 10.54% compared to the average of 9.33 of the last 4 quarters.
Chemomab Therapeutics Ltd. (CMMB) Historical Current Ratio (quarterly & annually)
How has CMMB Current Ratio performed in the past?
The mean historical Current Ratio of Chemomab Therapeutics Ltd. over the last ten years is 6.83. The current 10.31 Current Ratio has changed 15.00% with respect to the historical average. Over the past ten years (40 quarters), CMMB's Current Ratio was at its highest in in the September 2021 quarter at 40.39. The Current Ratio was at its lowest in in the June 2016 quarter at 0.
Average
6.83
Median
4.70
Minimum
0.59
Maximum
23.66
Chemomab Therapeutics Ltd. (CMMB) Current Ratio by Quarter and Year
Discovering the peaks and valleys of Chemomab Therapeutics Ltd. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 574.71%
Maximum Annual Current Ratio = 23.66
Minimum Annual Increase = -73.86%
Minimum Annual Current Ratio = 0.59
| Year | Current Ratio | Change |
|---|---|---|
| 2025 | 9.08 | 82.23% |
| 2024 | 4.98 | 15.40% |
| 2023 | 4.32 | -30.15% |
| 2022 | 6.18 | -73.86% |
| 2021 | 23.66 | 162.95% |
| 2020 | 9.00 | 103.58% |
| 2019 | 4.42 | 11.12% |
| 2018 | 3.98 | 574.71% |
| 2017 | 0.59 | -71.47% |
| 2016 | 2.07 | -11.10% |
Chemomab Therapeutics Ltd. (CMMB) Average Current Ratio
How has CMMB Current Ratio performed in the past?
The current Current Ratio of Chemomab Therapeutics Ltd. (CMMB) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
6.13
5-year avg
9.65
10-year avg
6.83
Chemomab Therapeutics Ltd. (CMMB) Current Ratio vs. Peers
How is CMMB’s Current Ratio compared to its peers?
Chemomab Therapeutics Ltd.’s Current Ratio is greater than Kazia Therapeutics Limited (2.87), greater than Ocean Biomedical, Inc. (0.06), greater than Theriva Biologics, Inc. (1.63), greater than PMGC Holdings Inc. (1.45), greater than Can-Fite BioPharma Ltd. (3.46), greater than BioVie Inc. (9.97), greater than XORTX Therapeutics Inc. (0.43), greater than InMed Pharmaceuticals Inc. (3.11), greater than CERo Therapeutics Holdings, Inc. (0.14), greater than Galmed Pharmaceuticals Ltd. (6.55),
| Company | Current Ratio | Market cap |
|---|---|---|
| 2.87 | $23.13M | |
| 0.06 | $118.64K | |
| 1.63 | $10.84M | |
| 1.45 | $2.85M | |
| 3.46 | $1.53M | |
| 9.97 | $12.29M | |
| 0.43 | $607.11K | |
| 3.11 | $2.73M | |
| 0.14 | $13.26K | |
| 6.55 | $3.35M |
Build a custom stock screener for Chemomab Therapeutics Ltd. (CMMB) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Chemomab Therapeutics Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Chemomab Therapeutics Ltd. (CMMB) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Chemomab Therapeutics Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the Current Ratio?
How can you use the Current Ratio?
What is Chemomab Therapeutics Ltd.'s Current Ratio?
How is the Current Ratio calculated for Chemomab Therapeutics Ltd. (CMMB)?
What is the highest Current Ratio for Chemomab Therapeutics Ltd. (CMMB)?
What is the 3-year average Current Ratio for Chemomab Therapeutics Ltd. (CMMB)?
What is the 5-year average Current Ratio for Chemomab Therapeutics Ltd. (CMMB)?
How does the current Current Ratio for Chemomab Therapeutics Ltd. (CMMB) compare to its historical average?